# Subagent Plan V3

**Started:** 2026-05-26 18:41 UTC  
**Principle:** subagents gather and stress-test evidence. They do not claim final findings. The orchestrator must verify and integrate.

## First-Wave Disease Specialists

Each disease specialist will answer:

1. Which public datasets are most tractable for the disease within this session?
2. Does the lipid-lysosomal inflammatory myeloid module appear in the relevant tissue/cell type?
3. Which candidate nodes are strongest, and which are contradicted?
4. What evidence channels exist: expression/cell state, genetics, perturbation/drug response, comorbidity, microbiome, immune repertoire?
5. What prior art blocks or supports the candidate mechanism?

Minimum diseases:

- multiple sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus / lupus nephritis
- Crohn's disease
- ulcerative colitis
- psoriasis
- type 1 diabetes
- Sjogren's syndrome
- ankylosing spondylitis
- myasthenia gravis
- autoimmune thyroid disease
- celiac disease
- primary biliary cholangitis

Deliverable: concise report with accessions, citations/links, candidate ranking, blockers, and proposed local analyses.

## First-Wave Modality Specialists

### Genetics

Scope: cross-autoimmune GWAS/eQTL evidence for candidate module genes and regulators. Validate instruments before any MR claim. Mark GWAS-overlap-only evidence as weak.

### Cell State And Spatial

Scope: identify cross-tissue macrophage/microglia states corresponding to lipid-lysosomal inflammatory myeloid programs and recommend accessible matrices.

### Perturbation And Foundation Models

Scope: provision State/Stack/Evo 2 or comparable models; identify real perturbation datasets for `IFI30`, `GPNMB`, `SPP1`, `CTSD`, `LIPA`, `CXCL10`, `NAMPT`, and regulatory programs. No fabricated model output.

### Druggability And Prior Art

Scope: for emerging central-node candidates, assess intervention points, existing chemical matter, clinical precedents, safety, and patents/trials.

### Cross-Domain Mechanism Transfer

Scope: oncology immunotherapy, aging, neurodegeneration, transplant tolerance, pregnancy immunology, viral neurology, and microbiome mechanisms that map onto lipid-lysosomal myeloid states.

## Critique Subagents

Spawn hostile review agents at the requested intervals or major milestones. Their task is to attack:

- confounding by tissue injury and myeloid density;
- overbroad pan-inflammation claims;
- false novelty;
- weak foundation-model substitutions;
- prior-art and safety blockers;
- intervention direction ambiguity.

## Dispatch Rules

- Subagents may browse and inspect local files but should not edit files unless explicitly assigned.
- Every report must separate verified facts from speculation.
- Every dataset accession and citation must be checkable.
- Failed searches and blocked datasets are useful and must be reported.
- The orchestrator will copy or summarize returned outputs under `phases/v3/subagents/`.

## First-Wave Allocation

The first dispatch is intentionally wide:

- 13 disease specialists, one per named disease or disease family;
- 5 modality specialists;
- 1 foundation-model feasibility specialist;
- 1 integration/hostile critique agent after the first batch begins returning.

If concurrency becomes unstable, diseases will be grouped into tissue families for the second wave, but the first pass keeps them separate to reduce anchoring.

## Wave 3 Dispatch - 2026-05-26 21:02 UTC

Reason for wave: after Milestone 1, the central mechanism has sharpened to an
IFN-gamma/HLA-II/GILT antigen-processing transition. The unresolved questions
are genetics, novelty/prior art, and expansion beyond the currently analyzed
direct h5ad tissues.

### Genetics/Colocalization Scout

Scope:

- Evaluate whether `IFNGR1/2`, `JAK1/2`, `STAT1`, `IRF1`, `CIITA/RFX5`,
  `IFI30`, `CTSS`, and HLA-II/CD74 loci have credible genetic anchoring across
  MS, Crohn disease, ulcerative colitis, psoriasis, Sjogren syndrome, PBC,
  celiac disease, RA, and SLE.
- Prioritize real colocalization/MR-ready public resources. If full coloc is
  not feasible, explicitly separate locus overlap, eQTL/protein QTL evidence,
  and true colocalization.

Deliverable:

- `phases/v3/subagents/wave3_genetics_report.md` with accessions, exact loci where
  possible, what is true vs not established, and a go/no-go recommendation for
  V3 genetic anchoring.

Pivot criteria:

- If no non-MHC candidate has genetic evidence across at least four diseases,
  recommend either central mechanism framing rather than single-gene framing, or
  a biomarker/intervention claim that does not overstate genetics.

### IFI30/State Novelty And Patent Scout

Scope:

- Determine whether `IFI30`/GILT inhibition, activation, or modulation has
  blocking prior art for MS, IBD, psoriasis, Sjogren, PBC, celiac disease, RA,
  or SLE.
- Separately assess prior art for an IFN-gamma/HLA-II/GILT/CD74 state biomarker
  used to stratify JAK/IFN/antigen-processing interventions.
- Search PubMed, Europe PMC, bioRxiv/medRxiv, ClinicalTrials.gov, Google
  Patents, and Espacenet query URLs.

Deliverable:

- `phases/v3/subagents/wave3_novelty_report.md` with closest prior art, explicit
  deltas, and whether a narrow novelty claim survives.

Pivot criteria:

- If IFI30 therapeutic modulation is already substantially claimed in
  autoimmune disease patents or trials, demote it to mechanistic effector only.

### Disease-Breadth Expansion Scout

Scope:

- Find the fastest tractable public single-cell/spatial or pseudobulk datasets
  for at least two additional autoimmune tissues beyond MS/IBD/psoriasis/
  Sjogren, prioritizing RA synovium, lupus nephritis kidney, PBC liver, celiac
  gut, T1D islet/immune, or autoimmune thyroid.
- Do not use whole-bulk signatures if cell-resolved data are accessible.
- Report direct URLs/accessions and whether local download is feasible in this
  workspace.

Deliverable:

- `phases/v3/subagents/wave3_disease_breadth_report.md` with candidate datasets,
  metadata quality, expected file sizes, and recommended next two downloads.

Pivot criteria:

- If cell-resolved matrices are too large or controlled, recommend a specific
  pseudobulk fallback and state why it is weaker.

## Wave 4 Dispatch Plan - 2026-05-26 22:01 UTC

Reason for wave: after the hour-3 hostile critique, broad IFN/HLA/CD74/APC
recurrence was demoted by IFN-residualization. The next wave is narrower and
adversarial: compare a revived lipid-lysosomal candidate against the residual
CD74/HLA receptor-state lane.

### LIPA / Lipid-Lysosomal Central Node Scout

Scope:

- Test whether `LIPA` is a stronger central node for the original
  lipid-lysosomal module than `ACSL1`, `NAMPT`, `IFI30`, or `CD74`.
- Use only real local outputs and verified public sources.
- Specifically inspect direct h5ad gene-level tables, MS GSE111972, thyroid
  spatial, druggability/prior art, and autoimmune genetics if feasible.

Deliverable:

- `phases/v3/subagents/wave4_lipa_scout_report.md`
- Required sections: evidence for, evidence against, disease breadth,
  mechanism, intervention tractability, prior-art blockers, exact next
  falsifying analysis.

Pivot criterion:

- If `LIPA` is only a stress marker or lacks support beyond two compartments,
  recommend demotion immediately.

### Residual CD74/HLA Receptor-State Scout

Scope:

- Determine whether the IFN-residual `mif_cd74_receptor_state` signal can be
  made into a precise cross-disease mechanism or only a stratification marker.
- Focus on MS white-matter microglia, Sjogren epithelial tissue, and T1D
  ductal/acinar cells; do not recycle generic IFN claims.
- Audit intervention points that specifically modulate CD74/HLA receptor-state
  biology without broad JAK/IFN blockade.

Deliverable:

- `phases/v3/subagents/wave4_residual_cd74_scout_report.md`
- Required sections: residual evidence, confounders, therapeutic handles,
  prior art, why it is or is not a V3 central node.

Pivot criterion:

- If the residual signal is too narrow, prior-arted, or not druggable, recommend
  using it only as a biomarker/stratifier.

### Foundation Gate Runner

Scope:

- Monitor whether State `adata_real.h5ad` opens and enables gene-resolved
  module scoring.
- If State remains blocked, make a CPU-feasible Geneformer installation/run
  plan specific enough that the orchestrator can execute it; do not run long
  jobs without explicit dispatch.

## Wave 18 Dispatch Plan - 2026-05-27 01:53 UTC

Reason for wave: CTSH, LAPTM5, and Mediator kinase are now demoted or parked.
The next branch must either find a stronger intervention route attached to the
shared lysosomal/APC state or convert the state into a defensible treatment
stratification/pharmacodynamic claim.

### Wave18-A Treatment-Response Dataset Scout

Scope:

- Search for public autoimmune treatment-response datasets with cell-resolved
  or compartment-resolvable transcriptomic data.
- Prioritize UC/IBD, psoriasis, RA, lupus nephritis, Sjogren, and MS.
- Test whether the V3 lysosomal/APC/HLA-II/IFN readouts predict baseline
  response or change pharmacodynamically after treatment.
- Avoid all-cell bulk-like scores when marker-derived or curated compartments
  are feasible.

Deliverable:

- `phases/v3/subagents/wave18_treatment_response_scout.md`
- Any scripts/outputs under `scripts/` and `phases/v3/results/wave18_treatment_response/`
  if local execution is feasible.

Pivot criterion:

- If no dataset enables a corrected baseline predictor, report the best
  pharmacodynamic-only evidence and recommend whether the biomarker branch
  should be stopped.

### Wave18-B Accessible Druggable State-Component Rescue

Scope:

- Starting from local cross-disease module components, look specifically for
  extracellular, membrane, receptor, secreted, or enzyme intervention points
  that remain after CTSH/CTSS/CD74/MIF/LGALS9 saturation concerns.
- Use local recurrence tables, ChEMBL/OpenTargets/ClinicalTrials/Google Patents
  where feasible, and return a go/park/no-go recommendation.
- Candidates may include but are not limited to glycan checkpoints, scavenger/
  complement uptake, Fc/complement receptors, galectins, lysosomal lipid
  transporters, SPP1/GPNMB/TREM-like routes, and myeloid checkpoint nodes.

Deliverable:

- `phases/v3/subagents/wave18_accessible_target_rescue.md`
- Optional reproducible script/output if a quantitative ranking is built.

Pivot criterion:

- Promote only if the node has cross-disease recurrence, plausible druggability,
  a non-saturated novelty angle, and an intervention direction that is not just
  pan-inflammatory suppression.

### Wave18-C Foundation-Model Candidate Rescue

Scope:

- Re-examine existing Geneformer and State-parse outputs to identify candidates
  whose in-silico perturbation predictions are stronger than CTSH and align
  with real perturbation data.
- Do not claim official State/Stack/Evo 2 output unless actually run.
- Compare candidate deletion/projection metrics against Mixscale/GSE162464/
  GSE294918 real perturbation evidence where available.

Deliverable:

- `phases/v3/subagents/wave18_foundation_rescue.md`
- Optional script/output under `phases/v3/results/wave18_foundation_rescue/`.

Pivot criterion:

- If all candidates are weak, recommend abandoning foundation-model promotion
  as a primary evidence channel and keeping it only as triage.

Deliverable:

- `phases/v3/subagents/wave4_foundation_gate_report.md`
- Required sections: State gate result, exact command to validate mapping,
  Geneformer feasibility, compute estimate, and hard invalid-output rules.

Pivot criterion:

- If neither State nor Geneformer can run valid named-gene predictions in this
  environment, recommend using Mixscale CRISPRi as substitute perturbation
  evidence and document the foundation-model blocker.

## Wave 5 Dispatch Plan - 2026-05-26 22:13 UTC

Reason for wave: all hour-4 candidate lanes failed the V3 bar. Pivot to
tissue-licensing axes that may sit upstream of both inflammatory myeloid and
resident-cell repair/stress states.

### OSM/OSMR Tissue-Licensing Axis Scout

Scope:

- Test whether `OSM/OSMR` is a better cross-autoimmune central node than the
  demoted IFN/CD74/LIPA/NAMPT lanes.
- Check local expression outputs, OpenTargets-style hits, genetics reports,
  perturbation/drug-response evidence, and prior art across IBD, RA, psoriasis,
  AS, MS, Sjogren, T1D, and thyroid autoimmunity.
- Treat `OSMR` genetic visibility as a lead, not proof.

Deliverable:

- `phases/v3/subagents/wave5_osmr_scout_report.md`
- Required sections: bottom line, genetics, cell-state evidence, perturbation
  evidence, druggability/intervention, prior art, falsifying next analysis,
  go/no-go for V3 central-node status.

### Complement/C1q Resident-Myeloid Axis Scout

Scope:

- Test whether complement/C1q (`C1QA`, `C1QB`, `C1QC`, C1q receptors,
  complement phagocytic state) provides a stronger cross-autoimmune mechanism
  than lipid-lysosomal single genes.
- Focus on resident myeloid phagocytosis, tissue damage, synapse/myelin
  pruning, lupus nephritis, IBD, psoriasis, MS, and Sjogren.
- Check druggability and prior art for C1q/C1s/C3/C5 and tissue-selective
  strategies.

Deliverable:

- `phases/v3/subagents/wave5_complement_scout_report.md`
- Required sections: bottom line, disease breadth, genetic anchoring,
  cell-state evidence, intervention feasibility, prior art, falsifying next
  analysis, go/no-go.

### OSMR/Complement Local Quant Worker

Scope:

- Add local code to quantify `OSM/OSMR` and complement/C1q candidate modules
  in existing direct h5ad and GSE111972 outputs.
- Include residual controls against IFN/APC, NF-kB, HIF/NAMPT, lipid, and
  lysosomal modules where possible.
- Do not overwrite existing scripts except by adding narrowly named V3 scripts
  and runner entries.

Deliverable:

- Code and outputs under `scripts/` and `phases/v3/results/` with a report
  `phases/v3/subagents/wave5_local_quant_report.md`.

Pivot criterion:

- If neither axis has at least three diseases with direction-stable,
  compartment-plausible signal after basic residual controls, recommend a new
  pivot before hour 6.
## Wave 15: CD74/CIITA/HLA-II Intervention-Point Forcing Wave

Dispatch timestamp: 2026-05-27 01:03 UTC.

Reason for wave:

- Completed tracks converge on a recurrent `CD74`/`CIITA`/HLA-II
  antigen-presentation state.
- Direct candidates tested so far (`SLC15A4/TASL`, `GSK3B`, `GPR65`,
  `CIITA/RFX5/CD74`) fail at least one hard gate: breadth, target-level
  genetics, foundation-model support, selectivity, or novelty.
- The next useful question is not "is the state real?" but "what
  targetable dependency controls the state without simply blocking all IFN or
  all MHC-II biology?"

Workers:

- Wave15-A, surface/trafficking dependency worker. Scope:
  identify druggable surface, endosomal trafficking, protease, chaperone, or
  glycosylation dependencies that correlate with or perturb the `CD74`/HLA-II
  state across existing local single-cell/spatial datasets. Write scope:
  `scripts/v3_wave15_surface_trafficking_dependency.py`,
  `phases/v3/results/wave15_surface_trafficking_dependency/`,
  `phases/v3/subagents/wave15_surface_trafficking_dependency.md`.

- Wave15-B, perturbation and drug-response worker. Scope:
  query already downloaded and public perturbation resources for compounds or
  genetic perturbations that reduce `CD74`/`CIITA`/HLA-II while preserving a
  narrower generic IFN/core viability profile. Write scope:
  `scripts/v3_wave15_perturbation_drug_response.py`,
  `phases/v3/results/wave15_perturbation_drug_response/`,
  `phases/v3/subagents/wave15_perturbation_drug_response.md`.

- Wave15-C, novelty/prior-art and translational feasibility worker. Scope:
  audit candidate intervention classes around antigen presentation trafficking
  (`CTSS`, `IFI30/GILT`, `CD74/MIF`, `HLA-DM`, endosomal acidification,
  lysosomal lipid handling, Fc/complement uptake, glycan checkpoints) across
  MS, IBD, psoriasis, Sjogren, T1D, RA, SLE, celiac, autoimmune thyroiditis,
  myasthenia, PBC, and ankylosing spondylitis. Write scope:
  `phases/v3/literature/wave15_prior_art_queries.tsv`,
  `phases/v3/subagents/wave15_prior_art_feasibility.md`.

Pivot criteria:

- Promote a candidate only if it has at least three disease/tissue supports,
  one perturbation/drug-response support, and no blocking prior art for the
  specific cross-autoimmune intervention use.
- Demote candidates that only recapitulate generic IFN/JAK blockade, broad
  MHC-II suppression, or known saturated mechanisms without a narrower
  therapeutic delta.

## Wave19: Controller Pivot After Wave18 Negative Gates

Dispatch timestamp: 2026-05-27 06:01 UTC.

Reason for wave:

- Direct state markers, accessible state components, cathepsins, CD44/SPP1,
  galectins, Mediator kinase translation, and baseline-response biomarker
  branches failed promotion gates.
- The next useful question is not another marker-ranking pass. It is whether a
  tractable upstream controller can reset the shared lipid-lysosomal/APC/HLA-II
  state without collapsing generic IFN biology or deleting reparative myeloid
  populations.

Workers:

- Wave19-A, tolerogenic myeloid checkpoint controllers. Scope:
  test inhibitory/tolerogenic myeloid checkpoint candidates including `VSIR`,
  `LILRB4`, `LAIR1`, `CD200R1`, `SIGLEC10`, `LILRB3`, `LILRB5`, `HAVCR2`,
  `TIGIT`, `BTLA`, and related axes. Evaluate local recurrence/state coupling,
  drug modality, intervention direction, prior art, and novelty. Write scope:
  `phases/v3/results/wave19_tolerogenic_checkpoint/` and
  `phases/v3/subagents/wave19_tolerogenic_checkpoint.md`.

- Wave19-B, lysosomal stress and lipid-handling controllers. Scope:
  test `TFEB/TFE3`, `MCOLN1/TRPML1`, `PIKFYVE`, `LIPA`, `NPC1`, `NPC2`,
  `GBA`, `GBA2`, `LRRK2`, `PPARG`, `NR1H3/NR1H2`, and related lysosomal,
  autophagy, cholesterol-efflux, and lipid-repair routes. Evaluate whether
  activation/inhibition direction is explicit and druggable. Write scope:
  `phases/v3/results/wave19_lysosomal_controller/` and
  `phases/v3/subagents/wave19_lysosomal_controller.md`.

- Wave19-C, hostile critique. Scope:
  attack the V3 package as if reviewing a therapeutic target nomination.
  Determine whether the lipid-lysosomal/APC module is more likely a
  damage-response biomarker, myeloid-abundance confounder, or nonspecific
  inflammation marker than a causal intervention axis. Write scope:
  `phases/v3/subagents/wave19_hostile_critique.md`.

Promotion criteria:

- A candidate must have cross-disease state support, at least one independent
  perturbation or mechanistic support channel, plausible modality and direction,
  no blocking prior art for the specific autoimmune use, and a lead indication
  where tissue delivery is feasible.

Demotion criteria:

- Demote classes that only provide generic immunosuppression, generic
  autophagy/lysosome toxicity, myeloid-abundance markers, or prior-art-saturated
  checkpoint/tolerance claims.

## Wave20: Unrestricted Successor Search

Dispatch timestamp: 2026-05-27 06:08 UTC.

Reason for wave:

- Wave19 local controller triage found no immediate promotion candidate.
- Prior unrestricted scans still contain under-reviewed `test_or_scout` genes
  outside the exhausted accessible/cathepsin/checkpoint/IFN marker set.
- The session should not assume the lipid-lysosomal/APC module is the only
  possible cross-autoimmune axis if it continues to fail therapeutic gates.

Workers:

- Wave20-A, unrestricted survivor stress test. Scope:
  evaluate `SNX10`, `DAP`, `FMNL2`, `TNFAIP8L1`, `PPIL3`, `NCK1`, `PLEK2`,
  `SEL1L3`, `AQR`, `C15ORF48`, and any adjacent survivor from
  `phases/v3/results/unrestricted_survivor_scan/unrestricted_survivor_candidates.tsv`.
  Apply hostile Wave19 gates: recurrence, residual specificity, perturbation,
  modality, safety, and prior-art delta. Write scope:
  `phases/v3/results/wave20_unrestricted_survivor/` and
  `phases/v3/subagents/wave20_unrestricted_survivor.md`.

- Wave20-B, genetic/druggable alternate-axis search. Scope:
  search for cross-autoimmune genetically anchored targets or pathways outside
  the current lipid-lysosomal/APC module that might still satisfy druggability
  and novelty gates. Use local OpenTargets/genetics files, public target/drug
  databases, and prior-art queries. Explicitly exclude already-demoted
  `NAMPT`, `SLC15A4/TASL`, `GSK3B`, `CTSH/CTSS`, `CD44/SPP1`, `PD-L1`,
  galectin, complement/Fc/TAM/TREM, and JAK/IFN generic routes unless the
  worker finds a genuinely new modality or population delta. Write scope:
  `phases/v3/results/wave20_genetic_druggable_altaxis/` and
  `phases/v3/subagents/wave20_genetic_druggable_altaxis.md`.

Promotion criteria:

- Must satisfy the Wave19 hard gates and provide a route to a therapeutic V3
  claim. Expression recurrence alone is insufficient.

Demotion criteria:

- Demote candidates that are intracellular marker proteins without modality,
  generic stress/proliferation genes, prior-art-saturated targets, or unsupported
  by real perturbation/foundation evidence.

## Wave21: Strict-Residual Druggability Scan

Dispatch timestamp: 2026-05-27 06:25 UTC.

Reason for wave:

- Wave19/Wave20 demoted the hand-curated module, checkpoint, lysosomal
  controller, survivor, and genetics-first candidate lists.
- `CONVERGENCE_CHECK_5.md` identifies the remaining non-redundant possibility:
  strict-residual candidates outside the exhausted lists that also have an
  actionable external druggability route.

Workers:

- Wave21-A, local/API residual-druggability scan. Scope:
  combine `broad_residual_gate`, broad h5ad, OpenTargets/local genetics,
  ChEMBL, UniProt, and prior exclusion files. Rank candidates that have strict
  residual survival plus plausible modality. Demote generic IFN/JAK/proteasome
  or core-machinery hits unless a new intervention delta is explicit. Write
  scope: `scripts/v3_wave21_residual_druggability_scan.py`,
  `phases/v3/results/wave21_residual_druggability_scan/`, and
  `phases/v3/subagents/wave21_residual_druggability_scan.md`.

- Wave21-B, novelty/modality hostile review for residual candidates. Scope:
  focus on plausible residual/druggable candidates surfaced locally or obvious
  from `CONVERGENCE_CHECK_5.md`, including `ATOX1`, `SQLE`, `LDLRAD3`, `IL15`,
  `CD82`, `PSME1/2`, `POMP`, and `IFITM2/3`. Search PubMed/Europe PMC,
  preprints, ClinicalTrials.gov, Google Patents, ChEMBL, and UniProt; identify
  blocking prior art, modality, direction, and safety risks. Write scope:
  `phases/v3/results/wave21_residual_candidate_prior_art/` and
  `phases/v3/subagents/wave21_residual_candidate_prior_art.md`.

Promotion criteria:

- Candidate must have strict residual support, disease breadth or a defensible
  lead-indication rationale, explicit intervention direction, actionable
  modality, and no blocking prior art.

Demotion criteria:

- Demote candidates that are only expression/stress markers, generic
  IFN/proteasome/JAK/core-machinery biology, repair-liability candidates, or
  known targets without a new population/modality delta.

## Wave23: Non-Expression-First Escape Routes

Dispatch timestamp: 2026-05-27 07:00 UTC.

Reason for wave:

- Wave22 closed `SQLE` and effectively closed the residual/druggability rescue
  branch.
- The next non-redundant paths must use independent evidence channels and must
  not collapse into another broad-expression rank.

Workers:

- Wave23-A, metabolite/barrier-repair circuit scout. Scope:
  test whether the cross-autoimmune lipid-lysosomal/APC state is better
  explained by a druggable metabolite-sensing or barrier-repair circuit than by
  a single residual gene. Candidate classes include AHR/tryptophan, bile-acid
  receptors (`NR1H4`, `GPBAR1`), lipid nuclear receptors (`PPARA`, `PPARD`,
  `PPARG`, `NR1H3`, `NR1H2`), short-chain-fatty-acid receptors (`FFAR2`,
  `FFAR3`, `HCAR2`), retinoid/VDR axes, S1P receptors, and
  eicosanoid/leukotriene sensors. Write scope:
  `scripts/v3_wave23_metabolite_barrier_circuit.py`,
  `phases/v3/results/wave23_metabolite_barrier_circuit/`, and
  `phases/v3/subagents/wave23_metabolite_barrier_circuit.md`.

- Wave23-B, genetics-first restoration modality scout. Scope:
  revisit genetically anchored negative regulators and autophagy/endolysosomal
  loci as restoration targets, not inhibitor targets. Candidate set: `PTPN2`,
  `SH2B3`, `TNFAIP3`, `CLEC16A`, `ATG16L1`, `GPR65`, `CARD9`, `IRF5`, `IL10`,
  `IL6R`, `TYK2`, plus any locally justified additions. Explicitly distinguish
  feasible current modalities from speculative restoration. Write scope:
  `scripts/v3_wave23_genetics_restoration_modality.py`,
  `phases/v3/results/wave23_genetics_restoration_modality/`, and
  `phases/v3/subagents/wave23_genetics_restoration_modality.md`.

- Wave23-C, treatment-response stratification scout. Scope:
  ask whether the shared lipid-lysosomal/APC module is more useful as a
  stratification biomarker than as a target. Search existing local
  treatment-response data and public trial/GEO resources for module-baseline or
  pharmacodynamic associations across anti-TNF, JAK/TYK, IL-17/IL-23,
  anti-CD20, S1P, fumarate, and integrin therapies. Write scope:
  `scripts/v3_wave23_treatment_response_stratification.py`,
  `phases/v3/results/wave23_treatment_response_stratification/`, and
  `phases/v3/subagents/wave23_treatment_response_stratification.md`.

Promotion criteria:

- A route must add at least one independent channel beyond expression:
  genetics with direction, perturbation, treatment response, validated model
  prediction, clinical biomarker association, or mechanistic metabolic logic
  with a feasible modality.

Demotion criteria:

- Demote routes with only expression evidence, known broad immunosuppressive
  prior art, no realistic delivery/intervention direction, response evidence
  explained by severity/generic inflammation, or sample size too small for an
  effect-size claim.

## Wave32: Downstream Resolution Rescue

Dispatch timestamp: 2026-05-27 07:56 UTC.

Reason for wave:

- Wave31 closed the direct dynamic-controller branch. `MED16_KO` is a strong
  primary macrophage perturbation comparator, but it is not a druggable
  intervention and the CDK8/CDK19 translation route lacks a demonstrated APC
  phenocopy.
- The next non-redundant therapeutic question is whether the recurrent
  lipid-lysosomal inflammatory state can be driven into resolution or tissue
  repair without suppressing generic IFN/HLA-II host-defense programs.

Workers:

- Wave32-A, cross-autoimmune efferocytosis/lipid-clearance target scan. Scope:
  MERTK/AXL/TYRO3/GAS6/PROS1, TREM2/APOE/LPL, LXR/ABCA1, PPAR/retinoid axes,
  GPNMB, CD300, LIPA/NPC1/NPC2, and related resolution programs across MS, RA,
  SLE, IBD, psoriasis, T1D, Sjogren, and PBC. Deliver promotable and no-go
  targets with evidence channels and blockers.

- Wave32-B, perturbation/dataset availability scan. Scope: identify real public
  perturbation datasets where resolution/efferocytosis/lipid-clearance nodes are
  activated or inhibited in macrophages, microglia, APCs, organoids, or
  inflammatory tissue models. Include GEO/ArrayExpress, Perturb-seq/CRISPR,
  LINCS/CMap caveats, and what would count as validation.

- Wave32-C, prior-art and translational feasibility attack. Scope: search
  literature, preprints, patents, and trials for resolution-axis interventions
  in MS and other autoimmune diseases. Separate agonism from inhibition. Deliver
  blocking prior art, safety liabilities, tissue-delivery feasibility, and
  viable lead-indication windows.

Promotion criteria:

- Candidate must have cross-disease state support, at least one independent
  perturbation or mechanistic validation channel, a feasible intervention
  direction that does not collapse into broad immunosuppression, and no blocking
  prior art for the specific autoimmune use.

Demotion criteria:

- Demote candidates that only mark phagocytes, only improve generic
  inflammation scores, require unselective nuclear-receptor/JAK/TNF suppression,
  have contradictory agonism/inhibition direction, or have blocking prior art in
  the claimed autoimmune indication.

### Wave32-D / Hour-9 Hostile Critique

Dispatch timestamp: 2026-05-27 08:03 UTC.

Scope:

- Attack Waves 30-32 after static niche-driver, dynamic-controller, and
  downstream-resolution routes all failed promotion gates.
- Decide whether the lipid-lysosomal/IFN-HLA-II module is exhausted as a
  therapeutic-discovery route under the V3 DoD.
- State whether `TREM2/APOE`, `MERTK/TAM`, `LIPA`, or `NPC1/NPC2` should be
  reopened and what exact evidence would be required.
- Recommend the next forced pivot outside the module if appropriate.

Agent:

- `019e6874-c729-78f3-a53c-240fce344fa0` (`Sartre`)

## Wave34: Post-CD226 Pivot Fleet

Dispatch planning timestamp: 2026-05-27 08:15 UTC.

Reason for wave:

- Wave33 rejected the `CD226`/`TIGIT` checkpoint pivot under strict local
  cell-state and prior-art gates: broad GWAS Catalog signal exists, but local
  disease-state support is weak, the MS anchor is absent, and oncology /
  immunotherapy prior art is dense.
- The remaining work before the active Hour-12 floor must not relax gates. It
  should instead test independent routes that could plausibly survive:
  genetics-first druggable targets, the `FPR2`/`ANXA1` pro-resolution branch
  surfaced by Wave32-A, and checkpoint/adhesion axes that have apparent genetic
  breadth but may be blocked by prior art.

Workers:

- Wave34-A, genetics-first target rescue. Scope: scan broad autoimmune
  genetics evidence already available in the workspace plus public lookup
  surfaces for druggable genes missed by expression-first screens. Hard gate:
  no promotion without target-resolved or at least locus-specific evidence in
  at least four autoimmune diseases and a plausible intervention direction.

- Wave34-B, `FPR2`/`ANXA1` efferocytosis branch. Scope: determine whether the
  pro-resolution biased-agonism route has enough MS and cross-disease support
  to move beyond a Crohn/UC/lupus-nephritis follow-up hypothesis. Hard gate:
  real perturbation evidence plus MS lesion/local support; colitis
  pharmacology alone is insufficient.

- Wave34-C, checkpoint/prior-art sanity check. Scope: attack `BTLA/HVEM`,
  `CD6/ALCAM`, `CD226/TIGIT`, `IL7R`, and `BACH2/IKZF` for novelty, modality
  direction, clinical saturation, and safety. Hard gate: if prior art or
  direction conflict is blocking, demote explicitly.

Promotion criteria:

- Candidate must have at least three independent evidence channels, including
  either target-level genetic support or disease-relevant perturbation support,
  plus feasible current modality and non-blocking prior art.

Demotion criteria:

- Demote candidates that are expression-only, module markers, checkpoint axes
  with direction conflict, transcription-factor restoration without modality,
  or already established/crowded autoimmune mechanisms without a new subgroup
  or disease-specific delta.

## Wave36: Corrected Perturbation Rescue And Critique

Dispatch planning timestamp: 2026-05-27 08:47 UTC.

Reason for wave:

- Wave35 initially exposed a mapping artifact: Ensembl-indexed perturbation
  datasets had low module coverage because failed Ensembl REST calls had been
  cached as empty mappings.
- The corrected Wave35 script now uses exact-symbol MyGene.info fallback
  mapping and recovers near-complete module coverage in Ensembl-indexed
  datasets.
- Corrected results still show `0` controller-like perturbation contrasts
  under the strict module-direction gate. Before demoting the downstream
  resolution route, test whether a gene-level controller is hidden by module
  averaging, and run a hostile critique of the corrected operationalization.

Workers:

- Wave36-A, gene-level perturbation controller rescue. Scope: use the corrected
  Wave35 outputs and raw perturbation datasets to ask whether individual genes,
  submodules, or perturbation contexts reveal a druggable controller missed by
  averaged module scores. Hard gate: no promotion without a specific target,
  consistent direction across at least two perturbation datasets, and a
  plausible autoimmune intervention route.

- Wave36-B, hostile critique. Scope: attack the corrected Wave35
  operationalization, the remaining `FPR2`/`ANXA1`, `RXR/LXR`, `IL10`,
  `MERTK/TAM`, `GPNMB`, and `LIPA` rescue routes, and define what evidence
  would be needed to justify continuing versus pivoting away.

Promotion criteria:

- Promote only if a perturbation-level controller shows resolution repair with
  lipid/APC uncoupling, stress guardrails, replication, and non-blocking
  druggability/novelty.

Demotion criteria:

- Demote if the strongest signals are state markers, broad nuclear-receptor or
  cytokine programs with known prior art, one-dataset-only effects, or
  directionally contradictory perturbations.

## Wave39: Accessibility-First Rescue After Resolution Closure

Dispatch planning timestamp: 2026-05-27 09:05 UTC.

Reason for wave:

- Corrected Wave35 plus Waves36-38 closed the active
  resolution/efferocytosis target-discovery route.
- Prior intracellular and module-controller screens repeatedly failed on
  druggability, directionality, prior art, or weak causal interpretation.
- The remaining orthogonal route before the active Hour-12 floor is to start
  from accessibility and breadth: surface, secreted, extracellular, or
  enzymatically reachable genes with broad cross-autoimmune recurrence, then
  ask whether any have not already been demoted.

Workers:

- Wave39 local orchestrator scan. Scope: scan broad cross-disease h5ad gene
  recurrence for accessible targets outside the already-demoted Wave18 list,
  merge UniProt accessibility, ChEMBL chemical matter, Europe PMC/ClinicalTrials
  saturation, MS-anchor evidence, and prior-demotion flags. Hard gate: no
  promotion without cross-disease breadth, MS anchor, accessibility, feasible
  modality, non-crowded novelty, and explicit therapeutic direction.

- Wave39-B hostile accessibility/prior-art critique. Scope: attack any
  accessible-target rescue candidate and identify cases where apparent novelty
  is just a renamed version of prior `CD44/SPP1`, galectin, complement, TAM,
  cathepsin, cytokine, or checkpoint biology.

Promotion criteria:

- Candidate must have at least five autoimmune diseases in local recurrence or
  at least four plus a strong MS anchor, a surface/secreted/extracellular
  intervention route, tractable modality, and no close prior-art or clinical
  saturation in the proposed autoimmune direction.

Demotion criteria:

- Demote genes that are core machinery, generic IFN/TNF/chemokine cytokine
  readouts, prior Wave18/Wave21/Wave22 exclusions, inaccessible intracellular
  state markers, repair/fibrosis markers with unsafe direction, or candidates
  whose prior art already covers the proposed autoimmune use.

## Wave42: FADS Genetics-First Lipid Branch

Dispatch planning timestamp: 2026-05-27 09:34 UTC.

Reason for wave:

- L1000/repurposing, accessibility, and resolution/efferocytosis routes are
  now closed as target-discovery branches.
- A remaining orthogonal possibility is a lipid-genetic mechanism that does
  not require strong differential expression in diseased cell atlases. The
  `FADS1/FADS2` desaturation locus has broad autoimmune mapped-gene recurrence
  and direct lipid-metabolism relevance, while `FADS1` has ChEMBL chemical
  matter.

Workers:

- Wave42 local orchestrator scan. Scope: audit `FADS1/FADS2` as a
  genetics-first lipid-desaturation route using local GWAS Catalog/OpenTargets
  summaries, local cell-state/residual evidence, ChEMBL, PubChem, Europe PMC,
  ClinicalTrials.gov, L1000 metadata, and a small assumption-explicit lipid
  mediator model. Hard gate: no promotion without target-level genetic
  direction or replicated perturbation validation.

- Wave42-B hostile literature/prior-art reviewer. Scope: independently assess
  whether `FADS1/FADS2` desaturation biology can plausibly serve as a
  cross-autoimmune lipid-module intervention point, and identify blocking prior
  art, mechanistic contradictions, or safety issues.

Promotion criteria:

- Promote only if the branch supplies target-level genetic direction, a
  plausible FADS1 intervention direction, independent local or perturbation
  support, feasible chemistry, and non-blocking autoimmune prior art.

Demotion criteria:

- Demote if the evidence is only mapped-gene recurrence at the 11q12 lipid
  locus, if intervention direction cannot be resolved, if cell-state/perturbation
  evidence is absent, or if FADS inhibition is blocked by lipid-development
  safety/prior-art constraints.

## Wave47-G: Late-Stage Overlooked-Route Critique

Dispatch planning timestamp: 2026-05-27 10:05 UTC.

Reason for wave:

- Wave46 closed the original central IFN/HLA-II/lysosomal antigen-processing
  intervention set.
- A hostile reviewer should test whether that closure missed a route that is
  not merely a relabel of IFN/JAK, CD74/HLA-II, CIITA/RFX5, IFI30/GILT, CTSS,
  ACSL1, FADS, CFB, NAMPT, or generic tolerance/costimulation.

Worker:

- Wave47-G hostile overlooked-route critique. Scope: search V3 artifacts and
  public prior-art/literature context for one or more overlooked therapeutic
  routes that could plausibly satisfy cross-disease breadth, MS anchor,
  target-level genetics or perturbation, feasible druggability/selectivity, and
  non-blocking prior art.

Promotion criteria:

- A suggestion must provide a genuinely new evidence route or a new testable
  mechanism, not just a narrative reframing of a demoted branch.

Demotion criteria:

- Demote any route whose only support is expression recurrence, generic
  inflammatory biology, crowded autoimmune pharmacology, or an indirect proxy
  already rejected by the local gates.

## Wave48-G: Resolution-Reopener Adversarial Audit

Dispatch planning timestamp: 2026-05-27 10:12 UTC.

Reason for wave:

- Wave47-G did not find a promotable route, but it highlighted two branches
  that are not simple relabels of the closed IFN/HLA-II/lysosomal axis:
  biased `FPR2/ANXA1` pro-resolution signaling and receptor-specific `CD300`
  tuning.
- These branches need a narrow adversarial audit before local closure because
  the usual family-level and bulk-expression summaries are weak
  operationalizations for ligand-biased resolution signaling and lipid-sensing
  checkpoint receptors.

Worker:

- Wave48-G resolution-reopener adversarial reviewer. Scope: independently
  assess whether `FPR2/ANXA1` biased agonism or receptor-specific `CD300A`,
  `CD300F/CD300LF`, or `CD300E` modulation has hidden support sufficient to
  reopen V3 therapeutic discovery. Search prior local artifacts plus current
  literature, patents, clinical trials, target/drug resources, and
  perturbation evidence. Emphasize directionality, receptor specificity,
  disease breadth, MS anchoring, and translational whitespace.

Promotion criteria:

- Promote only if a branch has receptor-specific or ligand-biased mechanism,
  direct disease-relevant perturbation support, at least plausible MS anchor,
  tractable modality, and non-blocking prior art.

Demotion criteria:

- Demote if support remains only dynamic expression, family-level CD300
  ambiguity, generic pro-resolution literature, weak MS evidence, unresolved
  perturbation, or prior art that already covers the autoimmune use.

## Wave49-G: PTPN22 Directionality and Modality Critique

Dispatch planning timestamp: 2026-05-27 10:24 UTC.

Reason for wave:

- Wave47 ranked `PTPN22` as the top reopen-only genetics-first route.
- `PTPN22` is exactly the kind of candidate where breadth can be misleading:
  the genetics are broad, but therapeutic direction, phosphatase-family
  selectivity, and disease-safe modulation are unresolved.

Worker:

- Wave49-G PTPN22 adversarial reviewer. Scope: determine whether `PTPN22`
  can be promoted from reopen-only to a therapeutic candidate under the V3
  gates, or whether it should remain no-go. Evaluate genetic directionality
  around R620W-like risk biology, MS relevance, cross-autoimmune breadth,
  PTP-family selectivity, available inhibitors/allosteric modulators, clinical
  and patent prior art, perturbation evidence, and safety liabilities.

Promotion criteria:

- Promote only if there is target-resolved causal direction, a disease-safe
  therapeutic modulation direction, feasible selective modality, at least
  plausible MS anchor, and non-blocking novelty.

Demotion criteria:

- Demote if broad genetics remain directionally unresolved, if chemical matter
  is inhibitor-only without disease-safe direction, if selectivity over other
  phosphatases is weak, or if the route is already crowded by autoimmune
  prior art.

## Wave50-G: GPR65 Acid-Sensing GPCR Critique

Dispatch planning timestamp: 2026-05-27 10:31 UTC.

Reason for wave:

- `GPR65` is a tractable GPCR with cross-autoimmune genetics, including MS in
  local OpenTargets summaries.
- The branch is likely blocked by direct IBD/autoinflammatory prior art and by
  weak/contradictory local cell-state evidence, but because GPCR druggability
  is unusually tractable it deserves a direct adversarial audit.

Worker:

- Wave50-G GPR65 reviewer. Scope: assess whether GPR65 agonism/PAM can become
  a V3 therapeutic candidate or remains no-go. Evaluate target-resolved
  genetics, directionality of acidic pH/cAMP biology, local cross-autoimmune
  cell-state evidence, MS relevance, GPCR chemical matter, clinical and patent
  prior art, and a plausible responder biomarker.

Promotion criteria:

- Promote only if non-IBD/MS target-resolved direction and disease-cell
  perturbation evidence support a selective agonist/PAM route with a novelty
  delta beyond existing GPR65 autoimmune/IBD patents.

Demotion criteria:

- Demote if support remains mapped genetics plus generic GPCR tractability, if
  local disease-cell evidence is contradictory, or if prior art already covers
  autoimmune/MS use.

## Wave53-G: MED16/Mediator Perturbation-First Druggability Review

Dispatch planning timestamp: 2026-05-27 10:56 UTC.

Agent: `019e6919-5f4a-79c0-b30f-45d977d3997d` (`Maxwell`).

Reason for wave:

- The late-stage rescue list is closed for promotion after Wave52.
- Existing direct perturbation outputs point to `Med16_KO` as the strongest
  selective suppressor of antigen-processing/MHC-II readouts, but `MED16`
  itself is not an obvious drug target.

Worker:

- Wave53-G adversarial translational reviewer. Scope: start from
  `phases/v3/results/wave15_perturbation_drug_response/` and
  `phases/v3/results/wave18_foundation_rescue/`; determine whether the strong
  `Med16_KO` perturbation can be converted into a druggable intervention such
  as CDK8/19, Mediator kinase-module, or transcriptional co-regulator
  modulation. Check cross-autoimmune prior art, safety, cell specificity, and
  whether this is distinguishable from broad transcriptional toxicity.

Promotion criteria:

- Reopen only if a druggable Mediator-related intervention has disease-relevant
  perturbation support, selective antigen-processing/lipid-module effects,
  plausible cross-autoimmune breadth, and non-blocking prior art.

Demotion criteria:

- Demote if all practical Mediator interventions are oncology/transcription-
  toxicity dominated, nonselective, or already covered by autoimmune prior art.

## Wave53-H: Treatment-Response Stratification Rescue Review

Dispatch planning timestamp: 2026-05-27 10:56 UTC.

Agent: `019e6919-609b-7973-b7e5-1d856126450e` (`Erdos`).

Reason for wave:

- Treatment-response stratification may be the only remaining route that can
  generate a translational contribution without claiming a new universal
  target.
- Prior local audits were strict and mostly negative, but a hostile re-review
  should verify that no subgroup signal was discarded only because it was not a
  target nomination.

Worker:

- Wave53-H hostile treatment-response reviewer. Scope: review
  `phases/v3/results/wave23_treatment_response_stratification/`,
  `phases/v3/results/wave26_treatment_response_strict_audit/`,
  `phases/v3/results/gse253006_tofacitinib*/`, and
  `phases/v3/results/wave18_treatment_response/`. Focus on anti-TNF RA,
  tofacitinib UC, IL-17/IL-23 psoriasis, anti-CD20 MS, fumarate MS,
  fingolimod MS, and rituximab RA.

Promotion criteria:

- Reopen only if a baseline biomarker or response mechanism survives
  multiple-testing control, generic-inflammation residualization, and at least
  one independent replication or a clear prospective enrichment design.

Demotion criteria:

- Demote if signals remain underpowered, non-replicated, post-treatment-only,
  or generic-inflammation dominated.

## Wave53-I: Cross-Domain Intervention Scout

Dispatch planning timestamp: 2026-05-27 10:56 UTC.

Agent: `019e6919-6223-7763-8b87-ef9a631356ab` (`Huygens`).

Reason for wave:

- Repeating the same V3 candidate list is no longer useful; the next branch
  should import intervention logic from adjacent fields into the module.

Worker:

- Wave53-I cross-domain scout. Scope: scan oncology immunotherapy, transplant
  tolerance, pregnancy immunology, viral neurology, aging biology, and
  regenerative medicine for mechanisms that could selectively modulate
  antigen-processing/lipid-repair myeloid states. Avoid re-promoting closed
  axes: IFN/JAK/TYK2, CIITA/RFX5/CD74/HLA, NAMPT, ACSL1, SQLE, GPR65, PTPN22,
  FAP, FXYD5, CCR6, TREM2, and IL10.

Promotion criteria:

- Shortlist only mechanisms with a specific intervention point, plausible
  disease-module connection, existing chemical or biologic modality, and a
  non-obvious novelty delta.

Demotion criteria:

- Return no shortlist if every candidate is prior-art blocked or lacks a
  testable connection to the module.

## Wave56-J: SP140 Genetics And Prior-Art Audit

Dispatch planning timestamp: 2026-05-27 11:23 UTC.

Agent: `019e692d-3375-76a1-925c-95168fc6fede` (`Turing`).

Reason for wave:

- Wave55 nominated `SP140` as the strongest non-closed external genetics plus
  local cell-state reopener, but it failed the coloc/MR-grade target-resolution
  gate and cannot be promoted from associated-target scores alone.

Worker:

- Wave56-J genetics/literature reviewer. Scope: audit whether `SP140` has
  target-resolved genetic evidence across MS, Crohn disease, ulcerative
  colitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, and
  Sjogren syndrome. Check GWAS/coloc papers, eQTL direction, monocyte/myeloid
  specificity, and prior art for `SP140` modulation in autoimmune disease.
  Produce a short report with verified citations or explicit "not found"
  statements.

Promotion criteria:

- Reopen if there is credible coloc/eQTL/pQTL or variant-function evidence in
  at least two autoimmune diseases plus at least one MS-relevant anchor.

Demotion criteria:

- Demote if evidence is Crohn-centric, marker-level, directionally ambiguous,
  or already framed as the same autoimmune therapeutic intervention in the
  literature/patent/trial record.

## Wave56-K: SP140 Perturbation And Druggability Audit

Dispatch planning timestamp: 2026-05-27 11:23 UTC.

Agent: `019e692d-34be-72e1-bf35-24aaa227525f` (`Godel`).

Reason for wave:

- Wave55 found no direct ChEMBL chemical matter or perturbation support for
  `SP140`, but `SP140` contains chromatin-reader domains and may have
  upstream/downstream intervention points.

Worker:

- Wave56-K perturbation/druggability reviewer. Scope: determine whether
  `SP140` or an immediately adjacent pathway has real perturbation evidence
  consistent with suppressing the lipid-lysosomal inflammatory myeloid module.
  Check LINCS/CMap, Perturb-seq, public CRISPR screens, protein domains,
  AlphaFold/UniProt domain annotations, bromodomain/PHD tractability, and
  chemically tractable neighbors. Do not infer that generic bromodomain drugs
  phenocopy `SP140` unless evidence supports that direction.

Promotion criteria:

- Reopen if there is target-specific perturbation evidence or a defensible
  druggable phenocopy with selectivity over broad chromatin toxicity.

Demotion criteria:

- Demote if intervention would require undruggable nuclear-body scaffolding,
  broad epigenetic suppression, or unvalidated pathway substitution.

## Wave56-L: IL12A Comparator And Prior-Art Control

Dispatch planning timestamp: 2026-05-27 11:23 UTC.

Agent: `019e692d-3631-7362-9c9e-9be11b448a81` (`Averroes`).

Reason for wave:

- `IL12A` passed Wave55 druggability/modality precedent and external genetics
  gates but failed local module support. It is useful as a comparator for how
  a tractable but likely prior-art-heavy candidate should look.

Worker:

- Wave56-L comparator reviewer. Scope: audit whether `IL12A`/IL-12p35 offers
  any non-obvious cross-autoimmune intervention distinct from existing
  IL-12/23p40 and IL-23p19 therapeutic programs. Check MS-specific risks,
  failed/successful trials, patents, and whether IL-12p35 selectivity has a
  plausible therapeutic window.

Promotion criteria:

- Reopen only if there is a clearly novel, target-selective, disease-specific
  angle not blocked by IL-12/23 prior art and compatible with the local module.

Demotion criteria:

- Demote if it is simply the known IL-12/23 axis or lacks local module
  support.

## Wave58-M: CXCR2 Therapeutic Reopener Audit

Dispatch planning timestamp: 2026-05-27 11:41 UTC.

Agent: `019e693e-220a-7b22-bf91-83afe0f71d6a` (`Curie`).

Reason for wave:

- Wave57 reopened `CXCR2` from a model-supported intervention-first screen:
  strong Geneformer support in IBD myeloid, local recurrence in Crohn disease,
  psoriasis, and ulcerative colitis, external autoimmune genetics in five
  diseases, and druggability/clinical score support. The concern is weak/no
  MS anchoring and likely crowded neutrophil/chemokine prior art.

Worker:

- Wave58-M `CXCR2` reviewer. Scope: audit whether `CXCR2` antagonism or
  biased modulation has a defensible cross-autoimmune lipid-lysosomal myeloid
  mechanism, not merely generic neutrophil recruitment blockade. Check MS,
  IBD, psoriasis, RA/AS genetics, perturbation/drug response, ChEMBL/drug
  candidates, CNS/tissue delivery, clinical trial history, safety, and patent
  prior art. Include whether CXCR2 is expressed in the relevant disease
  myeloid/APC state versus neutrophil contamination.

Promotion criteria:

- Reopen strongly only if `CXCR2` has a non-generic, cell-state-specific
  mechanism tied to the module, druggability with safe feasible exposure, and
  novelty not blocked by prior CXCR2 autoimmune/inflammatory trials/patents.

Demotion criteria:

- Demote if it is generic neutrophil chemotaxis, lacks MS relevance, fails
  tissue/cell specificity, or is prior-art blocked.

## Wave58-N: IL7R Therapeutic Reopener Audit

Dispatch planning timestamp: 2026-05-27 11:41 UTC.

Agent: `019e693e-2550-71e3-b0ca-6b333e602558` (`Cicero the 2nd`).

Reason for wave:

- Wave57 reopened `IL7R` from model support in RA myeloid dendritic cells
  plus broad Open Targets genetics including MS. The concern is that `IL7R`
  is a canonical lymphocyte survival axis, not the lipid-lysosomal myeloid
  module, and is likely crowded by anti-CD127/IL-7R therapeutic programs.

Worker:

- Wave58-N `IL7R` reviewer. Scope: audit whether IL7R/CD127 modulation can
  be reframed as a myeloid/APC-state intervention rather than a generic T-cell
  therapy. Check MS and cross-autoimmune genetics/coloc direction, tissue/cell
  expression, perturbation/foundation evidence, anti-CD127 or IL-7/IL7R
  therapeutics, trials, safety, and patents.

Promotion criteria:

- Reopen strongly only if there is target-resolved autoimmune genetics,
  model/perturbation evidence in relevant non-lymphocyte disease states or a
  stratified lymphoid-myeloid mechanistic chain, and an unblocked therapeutic
  route with plausible safety.

Demotion criteria:

- Demote if the axis is generic/crowded T-cell survival, directionally unsafe,
  not module-specific, or already covered by prior art.

## Wave58-O: Hostile Review Of Wave57 Reopeners

Dispatch planning timestamp: 2026-05-27 11:41 UTC.

Agent: `019e693e-23e0-7532-9833-4ddc202b6c7e` (`Meitner`).

Reason for wave:

- Wave57 produced two reopeners from foundation-model triage. A hostile review
  should prevent proxy-satisficing before either is promoted.

Worker:

- Wave58-O hostile reviewer. Scope: attack both `CXCR2` and `IL7R` as V3
  finding candidates. Focus on whether the Geneformer evidence is a weak
  operationalization, whether local expression signals are cell-composition
  artifacts, whether genetics are target-resolved, whether intervention is
  novel, and whether either can plausibly satisfy the V3 DoD.

Promotion criteria:

- Identify the stricter audit needed if one branch is salvageable.

Demotion criteria:

- Recommend closure if both branches are generic, crowded, or disconnected
  from the lipid-lysosomal myeloid mechanism.

## Wave60-P: C15ORF48/MOCCI Circuit Audit

Dispatch planning timestamp: 2026-05-27 12:00 UTC.

Agent: `019e694f-6d85-7521-91c4-f8561900121e` (`Galileo the 2nd`).

Reason for wave:

- Direct lysosomal enzyme modulation failed Wave59, but `C15ORF48/MOCCI`
  repeatedly appears as a disease-state mitochondrial/inflammatory switch in
  IBD/T1D local data. It could be a central circuit node rather than a direct
  drug target.

Worker:

- Wave60-P reviewer. Scope: audit whether `C15ORF48/MOCCI` and the
  `C15ORF48`/`NDUFA4` complex-IV switch can anchor the lipid-lysosomal
  autoimmune myeloid module. Check local V3 artifacts, published mechanism,
  real perturbation evidence, upstream/downstream intervention points,
  druggability, safety, MS relevance, and prior art across autoimmune disease.

Promotion criteria:

- Promote only if a selective, tractable intervention point can correct the
  switch or its pathogenic consequence without broad mitochondrial toxicity,
  and if MS/cross-disease evidence extends beyond IBD/T1D marker recurrence.

Demotion criteria:

- Demote if `C15ORF48` is a marker of generic inflammation, lacks a safe
  intervention point, lacks MS support, or prior art already covers the
  therapeutic use.

## Wave60-Q: OSM/OSMR Tissue-Niche Circuit Audit

Dispatch planning timestamp: 2026-05-27 12:00 UTC.

Agent: `019e694f-6db2-7cb3-aa28-98cabf336adb` (`James the 2nd`).

Reason for wave:

- The OSM/OSMR axis has repeated local tissue-niche signals and a plausible
  molecule-to-cell-to-tissue mechanism: OSM-producing inflammatory myeloid
  cells licensing OSMR/IL6ST tissue responses. It may explain part of the
  cross-autoimmune module without direct lysosomal targeting.

Worker:

- Wave60-Q reviewer. Scope: audit whether `OSM`/`OSMR`/`IL6ST` is a
  promotable cross-autoimmune circuit, comparator, or stratification-only
  axis. Check local V3 OSMR/complement outputs, treatment-response outputs,
  MS artifacts, genetics, perturbation evidence, anti-OSM/anti-OSMR/gp130/JAK
  therapeutic programs, safety, trials, patents, and novelty.

Promotion criteria:

- Promote only if a novel, specific therapeutic or stratification delta
  survives direct OSM/OSMR prior art and shows cross-disease plus MS relevance.

Demotion criteria:

- Demote if the result collapses to known IBD barrier-inflammation OSM biology,
  generic JAK/STAT modulation, or prior-arted anti-OSM/OSMR therapy.

## Wave60-R: Hostile Methods Review Of Circuit Pivot

Dispatch planning timestamp: 2026-05-27 12:00 UTC.

Agent: `019e694f-6dcc-7e33-a542-51547e080e16` (`Newton the 2nd`).

Reason for wave:

- Donor-level circuit coupling can become a polished but weak surrogate if it
  only rediscovers inflammation/composition. A hostile reviewer should define
  the minimum bar before any circuit result can enter `FINDING_V3.md`.

Worker:

- Wave60-R hostile reviewer. Scope: attack the circuit-level pivot, including
  donor-level module coupling, residualization, cross-tissue comparability,
  pseudo-replication, foundation-model token deletion, and treatment-response
  interpretation. Recommend whether to continue with circuit discovery,
  response stratification, or an external perturbation-first pivot.

Promotion criteria:

- Identify a defensible operationalization that would make circuit evidence
  interpretable as mechanism-supporting.

Demotion criteria:

- Recommend closure if circuit coupling remains a confounded expression
  surrogate without causal perturbation or response validation.

## Wave61-S: Perturbation-First Intervention Mining Audit

Dispatch planning timestamp: 2026-05-27 12:12 UTC.

Agent: `019e695a-06f6-7f02-9c29-cd1ecf93455a` (`Hegel the 2nd`).

Reason for wave:

- Wave60 hostile review closed donor-level expression coupling as an
  insufficient operationalization. The next defensible unit is the
  intervention, not the candidate gene: a perturbation must selectively reduce
  the lipid-lysosomal/APC pathogenic module while sparing generic IFN/NF-kB,
  stress, viability, and repair/efferocytosis guardrails.

Worker:

- Wave61-S reviewer. Scope: inspect existing V3 perturbation artifacts
  (`wave15_perturbation_drug_response`, `wave24_l1000_recurrent_reversal`,
  `wave27_l1000_unknown_deconvolution`, `wave35_resolution_perturbation`,
  `wave37_gse212008_crispr_efferocytosis_screen`,
  `wave53_perturbation_first_pivot`, `mixscale`) and identify intervention
  candidates whose evidence is genuinely perturbation-first rather than
  expression-first. Write only `phases/v3/subagents/wave61s_intervention_mining.md`.

Promotion criteria:

- Promote only interventions with real perturbation evidence, selectivity over
  generic inflammatory collapse, repair/efferocytosis or viability guardrails,
  and a tractable target/modality.

Demotion criteria:

- Demote interventions supported only by L1000 cell-line reversal, generic
  JAK/NF-kB collapse, broad transcriptional suppression, or prior-arted
  autoimmune use.

## Wave61-T: Translational Feasibility And Prior-Art Audit

Dispatch planning timestamp: 2026-05-27 12:12 UTC.

Agent: `019e695a-0760-7842-b806-107d1522eba4` (`Einstein the 2nd`).

Reason for wave:

- Several candidate perturbations have local mechanistic support but fail at
  translation: CNS/tissue exposure, safety, selectivity, chemical matter, or
  blocking prior art. The therapeutic claim cannot survive without this audit.

Worker:

- Wave61-T reviewer. Scope: for intervention candidates emerging from prior V3
  perturbation branches (`MED16`, `GSK3B`, `RFX5`, `CHUK`, `TNFRSF1A`,
  `RXR/LXR/PPAR`, `TREM2/TAM/efferocytosis`, `PDE/cAMP`, `CDK8/19/Mediator`,
  and any stronger candidate found locally), audit druggability, tissue/CNS
  delivery, existing chemical matter, biomarker readouts, trials, patents, and
  prior art across MS/IBD/psoriasis/RA/SLE/T1D. Write only
  `phases/v3/subagents/wave61t_translational_prior_art.md`.

Promotion criteria:

- Promote only a candidate with a non-blocked novelty delta and a feasible
  first-indication experiment.

Demotion criteria:

- Demote if the route is already directly patented/published for the named
  autoimmune use, lacks selective chemical or modality control, or cannot
  reach the relevant tissue safely.

## Wave61-U: Hostile Review Of Perturbation-First Branch

Dispatch planning timestamp: 2026-05-27 12:12 UTC.

Agent: `019e695a-0848-7cb0-8b1f-9fe41fbecc5a` (`Darwin the 2nd`).

Reason for wave:

- Perturbation data can still become proxy-satisficing if cell-line reversal,
  mouse macrophage screens, or non-autoimmune readouts are over-weighted. A
  hostile review should set the branch-specific no-go rules before synthesis.

Worker:

- Wave61-U hostile reviewer. Scope: attack the perturbation-first strategy,
  especially cross-species transfer, L1000 interpretability, CRISPR screen
  readout mismatch, module-score circularity, selectivity definitions, repair
  guardrails, prior-art leakage, and causal inference. Write only
  `phases/v3/subagents/wave61u_hostile_review_perturbation_first.md`.

Promotion criteria:

- Define a minimum credible bar for an intervention-level V3 finding.

Demotion criteria:

- Recommend abandoning the branch if all apparent hits are generic
  anti-inflammatory, broad transcriptional, or non-translatable artifacts.

## Wave62-V: Open Targets Credible-Set Target Resolution Audit

Dispatch planning timestamp: 2026-05-27 12:32 UTC.

Agent: `019e6967-377f-7582-a3fd-e31187f31749` (`Planck the 2nd`).

Reason for wave:

- Wave55 and Wave25 treated genetics as weak because paired local GWAS/eQTL
  summary statistics were unavailable. The Open Targets Platform API now
  exposes `study`, `credibleSet`, `l2GPredictions`, and `colocalisation`
  fields that may provide precomputed target-resolution evidence without
  OpenGWAS authentication.

Worker:

- Wave62-V reviewer. Scope: use Open Targets Platform GraphQL or local outputs
  to assess whether any cross-autoimmune candidate has target-resolved
  credible-set plus QTL-colocalisation evidence, especially in MS and at least
  three other autoimmune diseases. Focus on genes relevant to the
  lipid-lysosomal/APC module and genetically broad nodes from Wave55/34A.
  Write only `phases/v3/subagents/wave62v_opentargets_target_resolution.md`.

Promotion criteria:

- Promote only if target resolution goes beyond mapped-gene/Open Targets
  association scores: disease credible-set L2G support plus same-target QTL
  colocalisation, with directionality stated.

Demotion criteria:

- Demote if the evidence is only L2G without QTL support, only QTL in irrelevant
  tissues, only one disease, or blocked by prior-art/druggability/direction.

## Wave62-W: Hostile Genetics-First Review

Dispatch planning timestamp: 2026-05-27 12:32 UTC.

Agent: `019e6967-37a0-78d0-abcf-0389f03aec82` (`Anscombe the 2nd`).

Reason for wave:

- Genetics-first can still proxy-satisfice if L2G or colocalisation rows are
  treated as causal proof without disease-cell connection, direction,
  intervention, or module relevance.

Worker:

- Wave62-W hostile reviewer. Scope: attack Open Targets credible-set/L2G/QTL
  colocalisation as a V3 target-resolution method. Define the minimum bar for
  using these API outputs in a therapeutic claim and identify failure modes
  around HLA/MHC, pleiotropy, ancestry, QTL tissue mismatch, sign ambiguity,
  prior art, and druggability. Write only
  `phases/v3/subagents/wave62w_hostile_genetics_first.md`.

Promotion criteria:

- Provide a strict acceptance checklist for any genetics-first claim.

Demotion criteria:

- Recommend closure if credible-set/L2G/QTL evidence cannot bridge to the
  module and intervention.

## Wave63-X: SP140-To-Topoisomerase Transferability Audit

Dispatch planning timestamp: 2026-05-27 12:42 UTC.

Agent: `019e6976-4ee2-72a3-a4ad-19f7a330d34a` (`Beauvoir the 2nd`).

Reason for wave:

- Wave62 makes `SP140` one of the few rows with MS/Crohn/psoriasis target
  resolution plus local cell-state support, but prior sessions demoted direct
  SP140 modulation. Published Crohn work suggests an alternative intervention:
  rescuing SP140 loss-of-function macrophage defects through topoisomerase
  inhibition. The question is whether that rescue generalizes beyond Crohn
  enough to matter for V3.

Worker:

- Wave63-X reviewer. Scope: audit SP140 loss-of-function, topoisomerase
  rescue, macrophage state, and cross-autoimmune transferability using local
  artifacts plus verified public literature. Assess `TOP1`, `TOP2A`,
  `TOP2B`, and any lower-toxicity topoisomerase-modulating route. Write only
  `phases/v3/subagents/wave63x_sp140_topoisomerase_transfer.md`.

Promotion criteria:

- Promote only if there is evidence for SP140-loss or topoisomerase-high
  disease-cell state beyond Crohn, with plausible therapeutic window and
  intervention specificity.

Demotion criteria:

- Demote if topoisomerase rescue is Crohn-genotype-specific, cytotoxic,
  non-CNS-compatible, or already direct prior art for the claimed indication.

## Wave63-Y: Broad Genetics Benchmark Audit

Dispatch planning timestamp: 2026-05-27 12:42 UTC.

Agent: `019e6976-502a-7600-9b8f-9c13302706b5` (`Fermat the 2nd`).

Reason for wave:

- Wave62-V identified `BACH2` and `IRF5` as strong examples of broad
  cross-autoimmune target-resolved genetics. They should calibrate the
  evidence bar, but may not be V3 candidates.

Worker:

- Wave63-Y reviewer. Scope: compare `BACH2`, `IRF5`, `IL7R`, `STAT4`,
  `SP140`, and `IFI30` as genetics benchmarks. Determine whether any has a
  downstream intervention point that is both module-relevant and less blocked
  than direct target modulation. Write only
  `phases/v3/subagents/wave63y_broad_genetics_benchmark.md`.

Promotion criteria:

- Promote only a downstream/upstream intervention node with target-resolved
  genetics, disease-cell state evidence, and feasible modality.

Demotion criteria:

- Demote direct transcription-factor/cytokine-axis nominations that are
  prior-art, nonselective, wrong-direction, or outside the lipid-lysosomal/APC
  module.

## Wave63-Z: Hostile Transition-Controller Review

Dispatch planning timestamp: 2026-05-27 12:42 UTC.

Agent: `019e6976-5187-78c1-ba4a-4f8dd115a89b` (`Pascal the 2nd`).

Reason for wave:

- The local branch is about to infer controllers from intersections of prior
  analyses. This is high-risk for circularity, proxy-satisficing, and
  over-counting non-independent evidence.

Worker:

- Wave63-Z hostile reviewer. Scope: attack the transition-controller
  integration logic before it can harden into a narrative. Focus on
  independence of evidence channels, reuse of the same datasets, target versus
  marker distinction, lack of perturbation, directionality, druggability, and
  novelty. Write only `phases/v3/subagents/wave63z_transition_controller_hostile.md`.

Promotion criteria:

- Define minimum gates for any transition-controller claim to survive.

Demotion criteria:

- Recommend closure or reformulation if the proposed controller is just a
  marker, generic immune activation, or an already-demoted axis in new words.

## Wave64-A: Disease-Relevant Perturbation Dataset Scout

Dispatch planning timestamp: 2026-05-27 12:55 UTC.

Reason for wave:

- Wave63 closed genetics/expression/controller intersections because they
  still lacked direct human disease-relevant perturbation evidence. The next
  route must find real perturbation or treatment-response datasets that test
  direction, not another module overlap.

Worker:

- Wave64-A scout. Scope: search public repositories and literature for human
  autoimmune perturbation/treatment-response datasets relevant to the
  lipid-lysosomal/APC myeloid module, prioritizing MS, RA, Crohn's/UC,
  psoriasis, SLE, Sjogren's, T1D, and celiac disease. Include accessions,
  sample sizes, cell/tissue system, intervention, readout, whether raw data is
  feasible here, and a ranked recommendation for one dataset to analyze next.
  Write only `phases/v3/subagents/wave64a_perturbation_dataset_scout.md`.

Promotion criteria:

- Identify at least one feasible dataset with disease-relevant human cells,
  explicit perturbation or treatment exposure, adequate sample size or paired
  design, and genes/readouts sufficient to test the module and candidate
  intervention direction.

Demotion criteria:

- Demote datasets that are purely observational, non-human, missing raw data,
  underpowered without replication, or too generic to test direction.

## Wave64-B: Non-Expression Modality Scout

Dispatch planning timestamp: 2026-05-27 12:55 UTC.

Reason for wave:

- The V3 evidence stack is over-weighted toward transcriptomic module scores.
  A surviving claim needs orthogonal evidence such as proteomics,
  metabolomics/lipidomics, imaging, comorbidity, or clinical pharmacology.

Worker:

- Wave64-B scout. Scope: find public cross-autoimmune non-expression datasets
  or curated resources that can test the lipid-lysosomal myeloid module or a
  candidate intervention node. Prioritize proteomics, metabolomics/lipidomics,
  drug-response clinical datasets, imaging/radiomics, and comorbidity
  phenomics. Include exact accessions/resources, feasibility, variables, and a
  ranked recommendation. Write only
  `phases/v3/subagents/wave64b_nonexpression_modality_scout.md`.

Promotion criteria:

- Identify a feasible orthogonal dataset/resource that could support or refute
  a candidate independently of transcriptomic overlap.

Demotion criteria:

- Demote resources that are inaccessible, aggregate-only without target/module
  variables, or already covered by prior waves without new information.

## Wave64-C: Hostile Perturbation-Gate Review

Dispatch planning timestamp: 2026-05-27 12:55 UTC.

Reason for wave:

- Treatment-response and perturbation datasets are easy to overinterpret,
  especially when intervention affects global inflammation. A strict gate is
  needed before any pharmacodynamic or perturbation row can become a
  therapeutic claim.

Worker:

- Wave64-C hostile reviewer. Scope: define minimum acceptance rules for a
  perturbation-first V3 claim. Attack confounding by response, cell
  composition, generic inflammation, reverse causation, batch, endpoint
  circularity, drug-class non-specificity, wrong tissue, and prior-art leakage.
  Apply those rules to likely routes such as JAK/TYK, IL-17/23, anti-TNF,
  CD127/IL7R, SP140/TOP, lysosomal enzymes, and phagolysosomal modulators.
  Write only `phases/v3/subagents/wave64c_hostile_perturbation_gate.md`.

Promotion criteria:

- Produce clear go/no-go gates that can be implemented locally in the next
  script.

Demotion criteria:

- Recommend closure of the perturbation branch if all feasible datasets are
  weak surrogates for cell-intrinsic mechanism.

## Wave66-A: Metabolomics Workbench Extraction Scout

Dispatch planning timestamp: 2026-05-27 15:17 CEST.

Reason for wave:

- Wave65 showed that bulk treatment-response transcriptomics is dominated by
  generic inflammatory contraction. The next route must use a genuinely
  orthogonal biochemical modality and test whether lipid/metabolite classes
  converge across autoimmune diseases.

Worker:

- Wave66-A scout. Scope: determine exact programmatic access paths for the
  Metabolomics Workbench studies prioritized by Wave64-B: `ST001949`,
  `ST000899`, `ST002470`, `ST002732`, `ST002949`, `ST001636`, `ST001386`,
  `ST000422`, `ST003328`, and `ST000298`. For each, report whether
  individual-level processed data and sample metadata are downloadable without
  authentication, the relevant factors/case-control labels, file names/URLs,
  and any harmonization traps. Write only
  `phases/v3/subagents/wave66a_metabolomics_access_scout.md`.

Promotion criteria:

- Identify at least three autoimmune diseases with accessible feature matrices,
  metadata, and interpretable disease/control or pre/post contrasts.

Demotion criteria:

- Demote studies with summary-only data, missing phenotype labels, controlled
  access, or metabolite identifiers too ambiguous for class-level harmonization.

## Wave66-B: GSE282122 Cell-Resolved Perturbation Feasibility Scout

Dispatch planning timestamp: 2026-05-27 15:17 CEST.

Reason for wave:

- `GSE282122` is the strongest known disease-tissue, longitudinal, cell-resolved
  perturbation dataset for the current question, but the processed archive is
  large. We need to know whether a constrained myeloid/APC pseudobulk analysis
  is feasible before committing local compute.

Worker:

- Wave66-B scout. Scope: inspect public `GSE282122` supplementary files and
  metadata. Determine exact download URLs, archive contents if knowable without
  full download, cell-state annotations, subject/timepoint/remission metadata,
  and the minimal feasible analysis plan for V3 lipid-lysosomal/APC module
  testing. Include compute/memory risks and a go/no-go recommendation. Write
  only `phases/v3/subagents/wave66b_gse282122_feasibility.md`.

Promotion criteria:

- Show that a patient-level myeloid/APC pseudobulk perturbation analysis can be
  run without full atlas reintegration.

Demotion criteria:

- Demote if public files lack needed labels, require excessive memory/disk, or
  only expose raw data impractical for this session.

## 2026-05-28 Post-Wave137 Sidecars

Dispatch timestamp: 2026-05-28 07:51 CEST.

Workers:

- Maxwell (`019e6d29-6362-79e3-894d-50d5c632dc91`): read-only residual
  lipid-lysosomal successor search. Status: completed and closed. Output:
  parked falsification targets only, no finding.
- Turing (`019e6d29-7c6a-76a3-b510-1201f71a8797`): read-only genetics-first
  salvage audit. Status: completed and closed. Output: no clean genetics-first
  salvage target; `IFI30`, `SP140`, and `GALC` are comparator/falsification
  priorities only.
- Poincare (`019e6d29-97d1-7a41-b847-28d71f749be0`): read-only hostile
  critique of Waves 130-137. Status: completed and closed. Output: accepted
  methodological defects in cross-dataset replication, metadata labeling,
  module-score scaling, silent missing-input handling, Wave133 blocker parsing,
  Wave131 labels, and Wave137 mixed-response parsing.

Integration decision:

- No sidecar output is a finding.
- Poincare's methodological critique supersedes Wave130/Wave135 loose response
  replication calls until corrected reruns are complete.
## 2026-05-28 08:11 CEST - Post-Wave141 Orthogonal Pivot Sidecars

Purpose:
- After Waves 140-141 closed target-first and modality-first successor routes
  inside the lipid-lysosomal/APC package, dispatch read-only sidecars to find
  an orthogonal route and critique the pivot.

Agents:
- Ramanujan (`019e6d36-ecbd-7452-aff5-ca96b0d6929d`): treatment-response and
  resistance pivot audit using Wave84/Wave85-Wave89/Wave129 outputs.
- Chandrasekhar (`019e6d36-ed04-73c2-bb9e-db6d5aa4a14d`): orthogonal
  cross-autoimmune mechanism search outside lipid/APC and prior closed axes.
- Newton (`019e6d36-ed5c-7a51-89fc-988f518c3d68`): hostile critique of the
  pivot and of Waves 133-141.

Status:
- Returned and closed.

## 2026-05-28 09:16 CEST - Post-Wave158 Interface Pivot Sidecars

Reason:
- Wave158 closed CUX1/NFKBIZ/ELR as a promotable route.
- The next branch needs to avoid over-fitting to the first plausible
  perturbable receptor and should separate TWEAK/Fn14 prior-art saturation from
  other interface-cell intervention options.

Agents:
- Feynman (`019e6d70-546f-79d2-93dc-729ab6072a79`): read-only TWEAK/Fn14
  prior-art and translational saturation audit for `TNFSF12/TNFRSF12A`.
- Aquinas (`019e6d70-87db-7881-b004-919bc06f8089`): read-only non-ELR,
  non-CUX1/NFKBIZ interface intervention candidate scout from existing local
  V3 artifacts.

Status:
- Returned and closed.

Returns:
- Feynman: close `TNFSF12/TNFRSF12A` as a discovery target route. The local
  GSE237845 signal is real but TWEAK/Fn14 is heavily prior-art saturated across
  MS/EAE, IBD, RA, psoriasis, and lupus nephritis; BIIB023 has RA/lupus
  nephritis clinical precedent; broad autoimmune patents exist.
- Aquinas: no non-ELR candidate deserves promotion. Highest-priority next
  test is `LIFR/LIF` because GSE129487 contains direct siRNA signal outside
  CUX1/NFKBIZ/ELR, but it needs independent validation and cross-disease
  anchoring before a claim.

## 2026-05-28 09:51 CEST - Post-CUX1/ELR Critique Sidecar

Reason:
- Waves 153-156 reproduced a CUX1-linked ELR+ chemokine state but demoted it
  from direct intervention because of prior art and target-causality blockers.
- Need hostile review before reframing as a biomarker/state claim.

Agent:
- Epicurus (`019e6d69-6536-79d0-8c92-7f88036a210b`): hostile peer review of
  the CUX1/ELR stratification-biomarker salvage route.

Status:
- Running.

Return:
- Epicurus: hostile review says the CUX1/ELR reframing is only defensible as a
  low-priority state-marker hypothesis. It is not novel target biology, not yet
  an MS biomarker, and not clinically actionable without residual specificity,
  MS anchoring, and a named therapy-response endpoint.

Status:
- Returned and closed.

Returns:
- Ramanujan: anti-TNF response/resistance branch has inflammatory
  `IL1B/CXCL8/TREM1/OSM` plus `LAMP3` marker signal, but Wave88 proxy
  adjustment and prior art make it biomarker-only, not target-worthy.
- Chandrasekhar: no orthogonal mechanism promotable from current evidence;
  recommended a strict `CD58/CD2` adaptive-synapse forcing test as the only
  route with MS genetic anchor plus response/local signal.
- Newton: accepted critique that Waves 140-141 were scoped filters, not global
  exhaustion; required corrected wording, Wave136 stale-report correction,
  Wave133 supersession metadata, and explicit orthogonal gates.

## 2026-05-28 08:23 CEST - Post-Wave145 Fresh Architecture Sidecars

Reason for wave:
- Wave145 found zero promotable routes remaining inside the Wave83/Wave116
  lipid/APC intervention catalog after later post-closure vetoes.
- The next work should not recycle closed candidates. It should search outside
  the catalog for disease-first architecture mechanisms.

Planned agents:
- Planck (`019e6d42-b53e-7553-8044-ee7def5b905e`):
  tissue-entry/stromal-retention scout. Read-only scan for mechanisms recurring
  across autoimmune tissues but not reducible to lipid/APC marker programs.
- Gauss (`019e6d42-d52d-76c2-9d7e-d23484f61f7c`):
  genetics-first outside-catalog scout. Read-only scan for cross-autoimmune
  genetically anchored nodes not already killed by Wave83/Wave116/Wave145.
- Faraday (`019e6d42-ebfa-7a03-8719-dd496f0f58e1`):
  hostile critique scout. Read-only critique of the pivot and Wave145 route
  hygiene.

Status:
- Returned and closed.

Returns:
- Planck: best fresh architecture direction is barrier-interface
  retention/endothelial-stromal gating; proposes Wave146 module scan over
  endothelial entry, stromal retention, epithelial chemokine, TLS niche, and
  TL1A comparator modules. No finding claim.
- Gauss: no outside-catalog genetics-first candidate promotable; strongest
  benchmark is `TAGAP`/RhoGTPase-T-cell activation with `TNRC18` and `PUS10`
  comparators. No finding claim.
- Faraday: Wave145 is route hygiene but numerically over-penalized and brittle;
  do not treat its scores as calibrated. Architecture pivot is justified only
  if it avoids repeating stromal-marker proxy logic and implements a structured
  sender/receiver forcing test.

## 2026-05-28 08:23 CEST - Post-Wave150 Closure-Critique Sidecar

Reason:
- Waves 146-150 closed architecture-first, adaptive genetics, lymphoid niche,
  metabolite/barrier, and repurposing-first branches.
- Need a hostile check before accepting the local closure stack as directionally
  meaningful.

Agent:
- Euler (`019e6d52-f46d-75b1-8689-8d30173cbd37`): read-only hostile critique
  of Waves 146-150 and next-branch recommendation.

Status:
- Returned and closed.

Return:
- Euler: Waves 146-150 mostly valid for their scoped tests, but Wave146 is
  myeloid/APC-receiver-specific, Wave148/149 are conservative/proxy closures,
  and Wave150 is recurrent-L1000-specific rather than all repurposing. Priority
  next branch: `Wave151` interface-cell perturbation-first audit using real
  perturbation/LINCS/CMap/Perturb-seq evidence where available.

## 2026-05-28 08:50 CEST - External Interface Perturbation Data Scouts

Reason:
- Wave151 identified the missing requirement as real, disease-relevant human
  interface-cell perturbation data.
- The next branch needs external dataset discovery before a direct Wave152 can
  be built.

Agents:
- Darwin (`019e6d58-4468-7451-8982-38b3084b7c75`): epithelial/barrier-cell
  perturbation dataset scout for AHR, SCFA/HCAR/FFAR, bile-acid FXR/TGR5,
  retinoid/VDR, and epithelial chemokine rescue.
- Parfit (`019e6d58-6164-79b0-8b30-4a3276c93ebe`): endothelial, fibroblast,
  synovial fibroblast, stromal, pericyte, and mesenchymal perturbation dataset
  scout for barrier-entry and retention biology.
- Lovelace (`019e6d58-85ed-7fe3-8c52-16af984af860`): TLS/lymphoid-niche and
  LIGHT/HVEM/LTBR perturbation dataset scout.

Returns:
- Darwin: returned an epithelial/barrier shortlist. Highest immediate Wave152
  usability: `GSE190634` human colonoid cytokine response, `GSE217552` human
  keratinocyte TNF/IL17 drug rescue, `GSE200309` human iPSC-derived intestinal
  epithelial SCFA response, and `GSE162856` human colonic organoid VDR response.
- Lovelace: returned a TLS/LTBR shortlist. Best aligned datasets are
  `E-MTAB-10638/E-MTAB-10645` mouse `Ltbr` FRC/ILC niche perturbation,
  `GSE85895` weakly replicated human LIGHT/TNFSF14 MSC response, `GSE124649`
  mouse EAE FRC `Il17ra` perturbation, and auxiliary LTBR-lineage stromal
  references.
- Parfit: returned a stromal/endothelial shortlist. Highest immediate Wave152
  usability: `GSE129488` human RA/OA synovial fibroblast TNF/IL17 induction
  plus siRNA perturbation, `GSE213111` human endothelial TNF/IFNG time-course,
  `GSE237845` human colonic fibroblast TWEAK/TNFSF12 perturbation, and
  `SDY2213` RA FLS state/context bridge.

Status:
- Returned and closed.

## 2026-05-28 09:41 CEST - Post-Wave166 Modality Pivot Sidecars

Reason:
- Waves 164-166 depleted direct genetics-first, genetics-neighbor, and
  same-gene genetics/cell-state routes under corrected guardrails.
- Need independent read-only checks before pivoting to a different modality.

Agents:
- Boole (`019e6d84-c36b-78b2-837a-78da8426c106`): read-only modality-pivot
  scout over existing perturbation, foundation-rescue, repurposing-first, and
  intervention-first outputs. Deliverable: one or two concrete next script
  tests with local file/column references.
- Linnaeus (`019e6d84-dbfb-7b72-a1e9-eaf2e9943919`): read-only hostile
  critique of Waves 164-166 and current pivot logic, with three efficient
  falsification/rescue tests.

Status:
- Returned and closed.

Returns:
- Boole: route space is not empty, but remaining plausible pivots are modality
  pivots. Recommended two non-redundant tests: phenotype-first efferocytosis
  controller ranking from Wave37/Wave81/Wave166, and L1000 repurposing
  deconvolution from Wave150 joined to target/state evidence.
- Linnaeus: Wave166 depletion may be circular because inherited no-go labels
  and a manual closed-gene list gate eligibility. Recommended no-label shadow
  ranking, target-quality audit for apparent ChEMBL reachability, and
  C15-independent state validation.
